Volta Finance Limited : Misleading Website
24 May 2021
Volta Finance Limited (VTA / VTAS)
The Board of Volta Finance Limited announces the discovery of a website purporting to represent Volta Investment Group (“VIG”), an entity entirely unrelated to Volta Finance Limited (“the Company”). The website for VIG incorrectly notes that a number of the Directors of the Company are involved with VIG as members of their board. In addition to the incorrect information regarding their board, it was also noted that the Companies House (UK) Certificate of Incorporation displayed on the website of VIG does not match the details and documentation publically available from Companies House.
Further to the discovery of VIG’s website, the Company contacted the webhosting provider and the domain registrar of the website to alert them to the incorrect and misleading information regarding the involvement of the Company’s Directors with VIG, as well as the aforementioned Companies House documentation. Additionally, using the contact details on VIG’s website, the Company advised VIG of the incorrect information on their website, and specifically requested that any mention of the Company’s Directors be removed immediately and permanently.
As of publishing time, VIG’s website is still active, and the issues noted above have not been resolved to the Company’s satisfaction. The Company asserts that neither it, nor any of its Directors, are involved with VIG or any of its officers and/or subsidiaries. Additionally, the Company would like confirm that the sole legitimate website for the Company is www.voltafinance.com.
For the Investment Manager
AXA Investment Managers Paris
+33 (0) 1 44 45 84 47
Company Secretary and Administrator
BNP Paribas Securities Services S.C.A, Guernsey Branch
+44 (0) 1481 750853
Cenkos Securities plc
+44 (0) 20 7397 8900
ABOUT VOLTA FINANCE LIMITED
Volta Finance Limited is incorporated in Guernsey under The Companies (Guernsey) Law, 2008 (as amended) and listed on Euronext Amsterdam and the London Stock Exchange's Main Market for listed securities. Volta’s home member state for the purposes of the EU Transparency Directive is the Netherlands. As such, Volta is subject to regulation and supervision by the AFM, being the regulator for financial markets in the Netherlands.
Volta’s investment objectives are to preserve capital across the credit cycle and to provide a stable stream of income to its shareholders through dividends. Volta seeks to attain its investment objectives predominantly through diversified investments in structured finance assets. The assets that the Company may invest in either directly or indirectly include, but are not limited to: corporate credits; sovereign and quasi-sovereign debt; residential mortgage loans; and, automobile loans. The Company’s approach to investment is through vehicles and arrangements that essentially provide leveraged exposure to portfolios of such underlying assets. The Company has appointed AXA Investment Managers Paris an investment management company with a division specialised in structured credit, for the investment management of all its assets.
ABOUT AXA INVESTMENT MANAGERS
AXA Investment Managers (AXA IM) is a multi-expert asset management company within the AXA Group, a global leader in financial protection and wealth management. AXA IM is one of the largest European-based asset managers with 679 investment professionals and €858 billion in assets under management as of the end of December 2020.
This press release is published by AXA Investment Managers Paris (“AXA IM”), in its capacity as alternative investment fund manager (within the meaning of Directive 2011/61/EU, the “AIFM Directive”) of Volta Finance Limited (the "Volta Finance") whose portfolio is managed by AXA IM.
This press release is for information only and does not constitute an invitation or inducement to acquire shares in Volta Finance. Its circulation may be prohibited in certain jurisdictions and no recipient may circulate copies of this document in breach of such limitations or restrictions. This document is not an offer for sale of the securities referred to herein in the United States or to persons who are “U.S. persons” for purposes of Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or otherwise in circumstances where such offer would be restricted by applicable law. Such securities may not be sold in the United States absent registration or an exemption from registration from the Securities Act. Volta Finance does not intend to register any portion of the offer of such securities in the United States or to conduct a public offering of such securities in the United States.
This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Past performance cannot be relied on as a guide to future performance.
This press release contains statements that are, or may deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "anticipated", "expects", "intends", "is/are expected", "may", "will" or "should". They include the statements regarding the level of the dividend, the current market context and its impact on the long-term return of Volta Finance's investments. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Volta Finance's actual results, portfolio composition and performance may differ materially from the impression created by the forward-looking statements. AXA IM does not undertake any obligation to publicly update or revise forward-looking statements.
Any target information is based on certain assumptions as to future events which may not prove to be realised. Due to the uncertainty surrounding these future events, the targets are not intended to be and should not be regarded as profits or earnings or any other type of forecasts. There can be no assurance that any of these targets will be achieved. In addition, no assurance can be given that the investment objective will be achieved.
The figures provided that relate to past months or years and past performance cannot be relied on as a guide to future performance or construed as a reliable indicator as to future performance. Throughout this review, the citation of specific trades or strategies is intended to illustrate some of the investment methodologies and philosophies of Volta Finance, as implemented by AXA IM. The historical success or AXA IM’s belief in the future success, of any of these trades or strategies is not indicative of, and has no bearing on, future results.
The valuation of financial assets can vary significantly from the prices that the AXA IM could obtain if it sought to liquidate the positions on behalf of the Volta Finance due to market conditions and general economic environment. Such valuations do not constitute a fairness or similar opinion and should not be regarded as such.
Editor: AXA INVESTMENT MANAGERS PARIS, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6, Place de la Pyramide - 92800 Puteaux. AXA IMP is authorized by the Autorité des Marchés Financiers under registration number GP92008 as an alternative investment fund manager within the meaning of the AIFM Directive.
*****To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Karolinska Developments portföljbolag Aprea Therapeutics uppnår primärt utfallsmått i kombinationsterapi av AML med eprenetapopt17.6.2021 10:25:55 CEST | Pressemelding
STOCKHOLM, SVERIGE 17 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics rapporterar positiva resultat från en pågående fas 1/2-studie av bolagets läkemedelskandidat eprenetapopt i kombination med venetoklax och azacitidin i patienter med TP53-muterad akut myeloisk leukemi, AML. Studieresultaten visar att behandlingen uppnår studiens förutbestämda primära effektmått med fullständig remission i 37% av de utvärderade fallen. Studieresultaten baseras på en analys av 30 evaluerbara patienter där fullständig remission (CR) uppmättes i 37% av fallen. Den sammanlagda remissionsfrekvensen i kombination med ofullständig remission (CRi), CR/Cri, var 53%. Enligt studiens tillämpade design (Simon 2-stage) uppnåddes därmed det förutbestämda primära effektmåttet avseende fullständig remission. I den fortsatta delen av fas 1/2-studien ingår elva patienter som erhåller kombinationsterapin och monitoreras avseende säkerhet och behandlingse
Karolinska Development’s portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary efficacy endpoint in combination therapy of acute myeloid leukemia17.6.2021 10:25:55 CEST | Press release
STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2 study evaluating the efficacy of the company’s candidate drug eprenetapopt in combination with venteoclax and azacitidine in patients treated for TP53 mutated acute myeloid leukemia, AML. The results show that the primary efficacy endpoint of complete remission was reached in 37% of patients. The results are underpinned by an analysis performed on 30 evaluable patients, demonstrating complete remission in 37% of the cases. the composite response rate, i.e. CR combined with CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%. The pre-defined primary efficacy endpoint concerning complete remission was thus reached in accordance with the applied study design (Simon’s 2-stage). Eleven patients remain on the study treatment and is continuously monitored on safety and efficacy para
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS17.6.2021 10:10:00 CEST | Press release
RESULT OF RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS Auction date2021-06-17Loan192Coupon1.00 %ISIN-codeSE0010133207Maturity2023-03-15 Tendered volume, SEK mln800 +/- 400 Volume offered, SEK mln1,600Volume bought, SEK mln800Number of bids2Number of accepted bids1Average yield-0.064 %Lowest accepted yield-0.064 %Highest yield-0.064 %% accepted at lowest yield 100.00 Auction date2021-06-17Loan1588Coupon1.50 %ISIN-codeSE0011063015Maturity2024-03-01 Tendered volume, SEK mln2,000 +/- 1,000 Volume offered, SEK mln5,500Volume bought, SEK mln2,000Number of bids6Number of accepted bids2Average yield0.032 %Lowest accepted yield0.031 %Highest yield0.034 %% accepted at lowest yield 62.50 Auction date2021-06-17Loan151 Coupon1.00 %ISIN-codeSE0013486156Maturity2030-06-12 Tendered volume, SEK mln700 +/- 350 Volume offered, SEK mln1,600Volume bought, SEK mln700Number of bids4Number of accepted bids3Average yield0.853 %Lowest accepted yield0.851 %Highest yield0.861 %% accepted at lowest yield 71.43 Auc
Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark17.6.2021 10:00:00 CEST | Press release
Press Release Nokia accelerates Telenor and Telia joint 5G network rollout in Denmark Nokia to accelerate rollout following the availability of 3.5GHz spectrum; the enhanced services will offer premium 5G speeds to customers The move builds upon Nokia’s long-standing partnership with TTN as lead supplier of 5G RAN Radio 17 June 2021 Espoo, Finland – Nokia continues to build upon its ongoing business with leading Danish mobile operators, Telenor and Telia via their joint network (TTN) accelerating the delivery of 5G services nationwide following the availability of 3.5 GHz spectrum. Nokia is the exclusive supplier of 5G RAN and will support the modernization of the shared network ensuring TTN’s three million customers have the best connectivity experiences. The availability of spectrum in the 3.5GHz band will offer incredibly fast 5G speeds to customers. The modernization deal will focus initially on Denmark’s four largest cities before expanding to cover most Danish customers during 20
Share Buyback Transaction Details June 10 – June 16, 202117.6.2021 10:00:00 CEST | Press release
Share Buyback Transaction Details June 10– June 16,2021 June 17, 2021 - Wolters Kluwer today reports that it has repurchased 68,486of its own ordinary shares in the period from June 10, 2021, up to and including June 16, 2021, for €5.6million and at an average share price of €81.21. These repurchases are part of the share buyback program announced on February 24, 2021, under which we intend to repurchase shares for up to €350 million during 2021. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2021 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€)2021 to date 2,697,810191.971.13 For the period starting May 6, 2021, up to and including August 2, 2021, we have engaged a third party to execute €70 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association. Repurchased shares are added to
Board of Directors Declares Share Buyback17.6.2021 08:33:39 CEST | Press release
17 June 2021 Board of Directors Declares Share Buyback On 16 June 2021, Acron’s Board of Directors resolved that the Company repurchase its outstanding shares as envisaged by clause 2, Article 72 of the Federal Law On Joint-Stock Companies. The number of shares sought shall not exceed 4,053,400, which is 10 per cent of the authorised capital. The repurchase price shall be RUB 6,050 per share. Therefore, the buyback amount shall not exceed RUB 24.5 billion. Shareholders may apply for repurchase from 8 July 2021 through 6 August 2021 inclusive. The repurchased shares shall be paid on or before 21 August 2021. If the total number of shares tendered by the Company’s shareholders exceeds 4,053,400, shares shall be repurchased from selling shareholders on a pro rata basis. A notification of the share buyback shall be posted on the Company’s website at https://www.acron.ru/en on or before 17 June 2021. Media contacts: Sergey Dorofeev Anastasia Gromova Tatiana Smirnova Public Relations Phone:
Eurocastle Announces 2021 AGM Results and PDMR Dealing Notification17.6.2021 08:00:00 CEST | Press release
Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Eurocastle Announces 2021 AGM Resultsand PDMR Dealing Notification Guernsey, 17 June 2021 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) (“Eurocastle” or the “Company”) today announces the results of its 2021 Annual General Meeting held yesterday, 16 June 2021. All ordinary and extraordinary business tabled before the meeting in accordance with the Notice of Annual General Meeting circulated to shareholders on 26 May 2021 was approved. A copy of this Notice is available on Eurocastle’s website at www.eurocastleinv.com under Periodic Reports and Shareholder Communications in the Investor Relations Section. In addition the Company issued 1,000 ordinary shares to each of its three independent directors as part of their in-place compensation arrangements. By reference to its obligations under Article 19 of EU Regulation 596/2014, the Company is making public the following